Core Viewpoint - Tempus AI, Inc. has announced a strategic collaboration with Blood Cancer United to develop a patient-centered registry for pediatric acute myeloid leukemia, aiming to enhance precision medicine in this area [1] Company Summary - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - Blood Cancer United, formerly known as The Leukemia & Lymphoma Society, is the largest global nonprofit dedicated to supporting blood cancer patients, conducting research, and advocating for the community [1] Industry Summary - The collaboration targets pediatric acute myeloid leukemia (pAML), which is identified as a rare and aggressive form of blood cancer [1]

Core Insights - Tempus AI is focusing on monetizing clinical applications and healthcare software, including the development of TIME, an AI-powered clinical trial solution for oncology [1][9] - The introduction of Tempus Next, a care pathway intelligence platform, utilizes AI to identify care gaps and provide actionable insights to clinicians [2] - Tempus One, a generative AI assistant, offers AI-enabled services for clinical decision support and drug research, leveraging proprietary Large Language Model technology [3] Company Developments - Tempus is expanding its revenue opportunities and presence within hospital systems through its innovative digital tools [4] - The company’s stock has seen a modest increase of 0.2% over the past year, contrasting with a 29.4% decline in the industry [8] - Current valuation metrics show that Tempus trades at a forward Price-to-Sales ratio of 5.36X, slightly above the industry median of 5.34X [10] Financial Performance - The loss per share estimate for 2026 has widened from 21 cents to 37 cents over the past 30 days [11] - Current estimates for the upcoming quarters indicate a loss of 0.20 for the current quarter and a projected loss of 0.37 for the current year [12]

Core Insights - Tempus AI (TEM) is enhancing its leadership in precision medicine through impactful research initiatives and clinical validations, particularly in AI-driven diagnostics for cancer treatment decisions [1] Research and Clinical Validation - In January 2026, TEM's Immune Profile Score (IPS) was shown to more accurately predict outcomes for patients receiving immune checkpoint inhibitors (ICIs) compared to conventional biomarkers like tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 [2] - A study published in September 2025 in JCO Precision Oncology validated the clinical utility of the PurIST algorithmic diagnostic, providing the largest real-world evidence to date for guiding first-line treatment decisions in advanced pancreatic ductal adenocarcinoma (PDAC) [3] - In April 2025, TEM published a study in the Journal of Molecular Diagnostics supporting the xF+ non-invasive technique for detecting actionable variants, identifying clinically relevant biomarkers, and monitoring disease progression [4] Peer Updates - Illumina (ILMN) reported in November 2025 that whole-genome sequencing (WGS) reveals more about the genetic causes of common diseases than older methods, with rare variants identified through WGS accounting for much of the missing heritability in complex diseases [5] - Myriad Genetics (MYGN) presented new data at the 2026 ASCO-GU conference supporting its various cancer tests, highlighting its expanding role in cancer care [6] Stock Performance - Over the past year, Tempus' shares have increased by 15.8%, contrasting with a 25.3% decline in the industry, while the S&P 500 composite has improved by 24.2% [7] Valuation Metrics - TEM currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 5.67X, compared to the industry median of 5.34X, indicating an expensive valuation [10] - The loss per share estimate for 2025 has widened from 42 cents to 56 cents over the past 30 days [11]

Group 1 - Tempus AI Inc shares are experiencing an increase in trading value following a Buy rating from Needham analyst Ryan MacDonald, who has set a price target of $75 [1] - The company announced a study published in JCO Precision Oncology, which emphasizes the importance of advanced genomic profiling tools in identifying actionable findings for cancer patients in community oncology settings [1][2] - The study, conducted in collaboration with The Oncology Institute, revealed that advanced testing features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex testing identified treatment-relevant findings that standard testing might miss [2] Group 2 - Approximately 12% of patients in the study's cohorts had actionable findings linked to approved therapies, which were identified exclusively through advanced testing methods [3] - The results highlight the potential of comprehensive genomic profiling to enhance treatment options and improve access to targeted therapies and clinical trial opportunities [4] - Tempus is focusing on its AI-driven precision medicine platform, positioning its data and diagnostics capabilities as a key differentiator in oncology and healthcare analytics [4] Group 3 - Tempus AI shares have shown volatility over the past year, with a price range from a low of $37.23 to a peak of $103.25, followed by a significant pullback [5] - Currently, the stock is trading below its 20-day, 50-day, and 200-day moving averages, indicating ongoing downside pressure [5] - As of the latest publication, Tempus AI shares were up 3.83% at $52.85 [6]

Core Insights - Tempus AI, Inc. has published a study in JCO Precision Oncology demonstrating the importance of advanced genomic profiling features in identifying clinically actionable findings for cancer patients [1] - The study indicates that 12% of patients had potentially actionable findings linked to approved therapies that were only identified through advanced features like tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex testing [1] Group 1: Study Findings - Advanced genomic profiling (CGP) expands treatment options for cancer patients in community oncology settings [1] - Current guidelines from organizations like ASCO and NCCN lack specificity on essential features required in genomic panels, highlighting the need for comprehensive testing [1] - The study emphasizes that CGP's value extends beyond panel size, showcasing the utility of advanced testing features in capturing clinically relevant findings [1] Group 2: Company Overview - Tempus is a technology company focused on advancing precision medicine through AI applications in healthcare [1] - The company possesses one of the largest libraries of multimodal data, providing AI-enabled precision medicine solutions to physicians [1] - Tempus aims to enhance personalized patient care and facilitate the discovery and development of optimal therapeutics [1]

Core Insights - Tempus AI Inc. is a leader in AI-driven precision medicine, focusing on integrating AI technologies into healthcare to enhance patient outcomes [1] - The company collaborates with major pharmaceutical firms to improve the discovery and development of precision medicine biomarkers [1] Company Developments - On March 10, 2026, H.C. Wainwright set a price target of $95 for Tempus, indicating a potential increase of approximately 82.6% from its trading price of $52.03 [2] - Tempus has entered a strategic collaboration with Merck & Co. Inc. to advance AI-driven precision medicine, utilizing its advanced Lens Platform and significant GPU infrastructure for complex analyses [3] - This partnership aims to enhance Merck's oncology and broader therapeutic portfolios by identifying novel precision biomarkers and mechanisms of cancer cell resistance [4] Market Performance - Tempus' market capitalization is approximately $8.96 billion, with a trading volume of around 928,414 shares on NASDAQ [5] - The stock has fluctuated between a high of $104.32 and a low of $36.22 over the past year, despite recent declines coinciding with broader market sell-offs [4][5]

Core Insights - Tempus AI's strategic focus for 2026 is on expanding its AI-driven precision medicine platform, scaling the diagnostics business, enhancing data and AI capabilities, and strengthening relationships with healthcare providers and pharmaceutical companies, supported by a commercial pipeline with a total contract value exceeding $1.1 billion [2] Financial Performance - In 2025, Tempus reported total revenues of $1.3 billion, an increase of 83.4% year over year, with the Diagnostics segment generating $955.4 million, reflecting 111.5% year-over-year growth, driven by strong Oncology and Hereditary testing volumes [3][8] - The Data and Applications segment also saw significant growth, generating $316.4 million in revenues, up 30.9% year over year, attributed to strong momentum in the Insights data licensing business [3] Market Position and Competitors - Tempus peers, such as Inspire Medical Systems and 10x Genomics, are expected to maintain growth momentum, with Inspire benefiting from increased adoption of sleep apnea therapy devices and 10x advancing through demand for single-cell and spatial genomics technologies [4] Stock Performance - Over the past year, Tempus shares increased by 15.7%, contrasting with a 25.2% decline in the Zacks Medical Info Systems industry, while peers like Inspire Medical Systems saw a 64.9% drop, and 10x Genomics posted a gain of 96.5% [5] Growth Initiatives - Tempus anticipates strong growth in its oncology diagnostics segment, expecting a 30% growth rate driven by the increasing adoption of genomic sequencing in cancer care, supported by a comprehensive test portfolio [6][9] - The company is also focusing on scaling the Minimal Residual Disease (MRD) testing opportunity, which has shown a 56% quarter-over-quarter volume growth, with plans for gradual commercialization and reimbursement coverage [10][11] Clinical Applications and Software Development - Beyond diagnostics, Tempus is developing clinical applications and healthcare software, including AI-powered tools like TIME and Next, aimed at enhancing patient matching and care pathway intelligence, which will create new revenue opportunities and strengthen its data ecosystem [12] Future Outlook - According to the Zacks Consensus Estimate, Tempus is expected to see a 25.4% improvement in revenues for 2026, although earnings per share are projected to remain negative but improve by 39.3% over 2025 [13]

Group 1 - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the top 10 stock picks for 2026 by ARK Invest [1] - The company announced a strategic partnership with Merck to accelerate the development of AI-driven precision medicine, particularly in oncology [1][3] - Merck will utilize Tempus's de-identified data and technologies to enhance the discovery and development of candidate therapies [2][3] Group 2 - Following the Q4 earnings call, JPMorgan analyst Casey Woodring reduced the stock's price target from $80 to $60, maintaining a Neutral rating due to concerns over data visibility and outlook revisions [2][3] - As of March 4, the stock is rated as a Moderate Buy with an average upside potential of 52.5% [4] - The healthcare technology company focuses on using artificial intelligence to advance precision medicine [4]

Core Insights - ARK Invest's stock portfolio for 2026 highlights a focus on disruptive innovation, with a total portfolio value of $15.07 billion as of Q4 2025, down from $16.80 billion in the previous quarter [2][3] Group 1: Portfolio Overview - The portfolio consists of 196 positions, reflecting a strategic shift towards increasing stakes in companies like Coinbase, CRISPR Therapeutics, and Tempus AI, while reducing positions in major names like Tesla and Shopify [2][3] - Cathie Wood, CEO and CIO of ARK Invest, anticipates strong deflationary pressures in 2026, particularly in energy, housing, and unit labor prices [3] Group 2: Top Stock Picks - **Tempus AI, Inc. (NASDAQ:TEM)**: Stake value of $446.3 million, with a strategic partnership with Merck to enhance AI-driven precision medicine [8][9] - **Teradyne, Inc. (NASDAQ:TER)**: Stake value of $456.1 million, with a recent revenue growth of 44% year-over-year to $1.08 billion in Q4 2025 [11][12] - **Robinhood Markets, Inc. (NASDAQ:HOOD)**: Stake value of $543.6 million, reporting a record quarterly revenue of $1.28 billion for Q4, despite missing analyst estimates [14][17] - **Advanced Micro Devices, Inc. (NASDAQ:AMD)**: Stake value of $551.4 million, with a recent price target increase following a strategic partnership with Meta [19][20] - **CRISPR Therapeutics AG (NASDAQ:CRSP)**: Stake value of $551.8 million, with strong momentum in siRNA therapies and a recent revenue of $54 million for Q4 [23][26]

Core Insights - The Diagnostics segment of Tempus AI (TEM) saw significant growth in 2025, primarily due to the increasing adoption of precision oncology testing and the integration of artificial intelligence with genomic diagnostics [1][10] - Minimal Residual Disease (MRD) testing emerged as one of the fastest-growing areas within Diagnostics, highlighting the rapid adoption of advanced monitoring technologies in cancer care [1][10] - Tempus' extensive clinical network, which includes over 5,500 hospitals and more than 8,500 regularly ordering oncologists, supports the strong performance of the diagnostics segment [1] Diagnostics Growth Factors - Tempus' multi-assay genomic testing platform, which includes advanced oncology tests such as xT, xR, xF, xH, and xE, has significantly contributed to the growth of the diagnostics segment [2] - The integration of artificial intelligence and multimodal data analysis into Tempus' diagnostic platform has been a major factor in advancing the diagnostics segment [2] - Innovative tools like Paige Predict, which analyzes digitized pathology slides to predict genetic mutations, and the Immune Profile Score, which refines traditional biomarkers, further enhance Tempus' diagnostic capabilities [3] Strategic Acquisitions - The acquisition of Ambry Genetics has strengthened Tempus' diagnostics segment by expanding its capabilities in hereditary cancer testing and broadening its overall sequencing portfolio [4] Industry Updates - Illumina (ILMN) is focusing on its core strengths in genomics, with the clinical market being a primary growth driver as sequencing adoption expands globally [5] - Illumina launched BioInsight, a new business aimed at providing comprehensive data solutions, with its first product, Billion Cell Atlas, attracting interest from biopharma partners [6] - Guardant Health (GH) made advancements in precision oncology and liquid biopsy testing, particularly with its Guardant360 liquid biopsy test and the expansion of its MRD testing platform, Guardant Reveal [7][8]